Showing results (331-340 of 358) with videos related to
Sort By:
Pageof 36
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 3, 2023
Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individualsPamela C L Ferreira, Joseph Therriault, Cécile Tissot, et al.Nature|March 24, 2006
Human chromosome 11 DNA sequence and analysis including novel gene identificationTodd D Taylor, Hideki Noguchi, Yasushi Totoki, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersJoão Pedro Ferrari-Souza, Guilherme Povala, Nesrine Rahmouni, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 15, 2023
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathologyBruna Bellaver, Albert Puig-Pijoan, João Pedro Ferrari-Souza, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target RegionsCécile Tissot, Stijn Servaes, Firoza Z Lussier, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Pamela C L Ferreira, et al.Molecular Psychiatry|August 10, 2022
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's diseaseJoão Pedro Ferrari-Souza, Pâmela C L Ferreira, Bruna Bellaver, et al.Nature Medicine|May 29, 2023
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Pamela C L Ferreira, et al.Brain : a Journal of Neurology|January 29, 2025
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrumJaime Fernández Arias, Wagner S Brum, Gemma Salvadó, et al.The Journal of Prevention of Alzheimer'S Disease|June 5, 2025
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's diseaseSarah Abbas, Pamela C L Ferreira, Bruna Bellaver, et al.Pageof 36